Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.UK-based Enigma Diagnostics has signed a term sheet for two patent license agreements with Roche Molecular Systems, a developer of molecular-based diagnostic tests.
Subscribe to our email newsletter
The licenses will provide Enigma full access under patents owned or licensed by Roche Molecular Systems and its affiliates to practice HybProbe real-time polymerase chain reaction (PCR) chemistry.
They will also allow Enigma to commercialize HybProbe diagnostic PCR tests for human and veterinary in vitro diagnostics on a worldwide basis, complementing the company’s existing license under patents owned by Celera Diagnostics for real-time PCR thermal cyclers.
Enigma is currently developing a series of multiplexed, HybProbe assays for infectious diseases including chlamydia, influenza and methicillin-resistant Staphylococcus aureus. These tests will be combined with Enigma’s fully automated real-time PCR system, the Enigma ML, to enable one-step molecular testing at point of care.